Bayer's Critical Countdown: A Month of Legal and Operational Reckoning

Bayer faces a pivotal U.S. Supreme Court hearing on glyphosate lawsuits in late April, amid a planned €5B negative cash flow for 2026. The firm reaffirms 2026 guidance and focuses on new drugs for growth.

For Bayer, the coming weeks represent a defining moment where long-term legal strategy collides with immediate financial reality. The German life sciences giant faces a concentrated series of events in late April that will shape its trajectory for years to come, testing investor confidence built on a remarkable 100.94 percent stock surge over the past year to €40.12.

The focal point is the U.S. Supreme Court. On April 27, justices will hear arguments in a pivotal case concerning federal preemption of state-level warning label claims related to glyphosate. A favorable ruling for Bayer could dramatically stem the tide of future Roundup litigation, a legal morass that has cost the company over $11 billion in settlements and judgments since its 2018 acquisition of Monsanto. The outcome is so crucial that management’s first public commentary on its position is anticipated alongside the Q1 2026 results on May 12.

This legal uncertainty directly pressures Bayer’s finances. For the current year, the company is planning for a substantial negative free cash flow of approximately €5 billion, a figure that fully accounts for continued payments from its legacy legal battles. This cash drain persists despite underlying operational resilience.

On the business front, Bayer projects stability. The company has reaffirmed its full-year 2026 guidance, expecting currency-adjusted sales to hold steady with an EBITDA ranging between €9.6 billion and €10.1 billion. Chief Operating Officer Sebastian Guth stated earlier this month that potential U.S. import tariffs on European pharmaceuticals are already factored into forecasts. An existing EU-US trade framework caps these levies at 15 percent for most medicines, mitigating the immediate threat.

Investor attention will first turn to the virtual Annual General Meeting on April 24. Shareholders are set to approve a dividend of €0.11 per share for fiscal 2025, matching the previous year's payout. The ex-dividend date is April 27, with payment following on April 29. The meeting will also formalize a refresh of the supervisory board, welcoming OMV CEO Alfred Stern and former Cargill executive Marcel Smits. They replace long-standing members Paul Achleitner and Colleen Goggins, a move stakeholders hope will inject fresh momentum into governance and sustainability efforts.

Beyond managing legacy issues, Bayer is building its growth foundation. The prostate cancer drug Nubeqa generated nearly €2.4 billion in revenue last year. The company aims for its pharmaceuticals division to return to mid-single-digit percentage growth from 2027 onward, targeting an expansion of its operating margin toward 30 percent by the end of the decade. Further bolstering the pipeline, the anticoagulant Asundexian has received Fast-Track status from the U.S. FDA, accelerating its regulatory review process.

While the share price has more than doubled from its low near €20 in April 2025, it remains about 18 percent below its 52-week high of €49.17. The stock’s performance reflects a market weighing robust operational forecasts against a daunting cash outflow. The verdict from Washington, and the subsequent corporate commentary in May, will determine whether Bayer’s ambitious mid-term goals are achievable or if the shadow of litigation will loom larger for longer.